- Pipecuronium bromide
-
- $8.00 / 1KG
-
2024-04-09
- CAS:52212-02-9
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: g-kg-tons, free sample is available
|
| | Pipecuronium bromide Basic information |
| Product Name: | Pipecuronium bromide | | Synonyms: | pipecuronium bromide;4,4'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1,1-dimethyl-piperazinium) dibromide;4,4'-[(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetoxy)androstane-2,16-diyl]bis[1,1-dimethylpiperazinium] dibromide;PIPECURIUM BROMIDE;PIPECURINIUM BROMIDE;4，4’-[(2β，3α，5α，16β，17β)-3，17-Bis(acetoxy)andrc~tane-2，16-diyl]bis(1，1-dimethylpiperazinium)dibromide;Ardtm;Pipecuriurn Brmnide | | CAS: | 52212-02-9 | | MF: | C35H62Br2N4O4 | | MW: | 762.69918 | | EINECS: | 257-740-4 | | Product Categories: | | | Mol File: | 52212-02-9.mol |  |
| | Pipecuronium bromide Chemical Properties |
| Melting point | 262-264° (dec) | | alpha | D25 +8.1° (c = 1 in water) | | storage temp. | Store at -20°C | | solubility | DMSO, Methanol (Slightly), Water (Slightly) | | form | Solid | | color | White to Off-White | | CAS DataBase Reference | 52212-02-9(CAS DataBase Reference) |
| Toxicity | LD50 in mice, rats (mg/kg): 29.7, 172.6 i.v.; 70.6, 449.6 i.p.; 60.5, 455.8 s.c. (Kárpáti, Biro) |
| | Pipecuronium bromide Usage And Synthesis |
| Uses | Pipecuronium Bromide is a muscle relaxant and an anaesthesia used in patients undergoing coronary artery bypass graft surgery. | | Definition | ChEBI: Pipecuronium bromide is a steroid ester. | | Brand name | Arduan (Organon). | | General Description | Pipecurium bromide, 4,4 -(3 ,17 -dihydroxy-5 -androstan-2 ,16 -ylene)bis(1,1-dimeth-ylpiperazinium)dibromide diacetate (Arduan), is anondepolarizing muscle relaxant similar, both chemicallyand clinically, to pancuronium bromide. It is a long-actingdrug indicated as an adjunct to anesthesia and in patients undergoingmechanical ventilation. | | Pharmacology | Pipecuronium bromide, an analogue of pancuronium, was developed in
Hungary in 1980 and is marketed in Eastern Europe and the United S tates.
The intubating dose is 0.07 mg kg–1. The onset time and time to recovery from
block are similar to those of pancuronium, and excretion of
the drug through the kidneys is significant (66%). In contrast to
pancuronium, pipecuronium produces marked cardiovascular stability,
having no vagolytic or sympathomimetic effects. It may therefore be useful
during major surgery in patients with cardiac disease. |
| | Pipecuronium bromide Preparation Products And Raw materials |
|